Heterobicyclic compounds useful as p38 kinase inhibiting agents
Details for Australian Patent Application No. 2006280090 (hide)
International Classifications
Event Publications
13 March 2008 PCT application entered the National Phase
PCT publication WO2007/021710 Priority application(s): WO2007/021710
28 January 2010 Alteration of Name
The name of the applicant has been altered to Merck Sharp & Dohme Corp.
1 March 2012 Application Accepted
Published as AU-B-2006280090
28 June 2012 Standard Patent Sealed
11 October 2012 Alteration of Name
The name of the patentee has been altered to Merck Sharp & Dohme Corp.
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2006280091-Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
2006280076-Methods and apparatus for hot air sterilization of medical instruments
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser